{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:35:53Z","timestamp":1779312953370,"version":"3.51.4"},"reference-count":11,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>ABSTRACT  Background  - Terlipressin and noradrenaline are the best studied treatments for hepatorenal syndrome, and there is no evidence of superiority of one over the other regarding to efficacy. While the former drug is more costly, the latter requires admission into an intensive care unit.  Objective  - The aim of this study was to perform an economic evaluation, comparing treatments for hepatorenal syndrome with terlipressin and noradrenaline.  Methods  - For the economic evaluation, a cost-minimization analysis was performed. Direct medical costs of the two treatment strategies were compared under the perspective of the Brazilian Public Health System as the third-party payer. A probabilistic sensitivity analysis was performed.  Results  - The costs of treatments with terlipressin or noradrenaline were 287.77 and 2,960.45 International Dollars (Int$) respectively. Treatment using terlipressin would save Int$2,672.68 for the Public Health System for each hospital admission related to hepatorenal syndrome. In the probabilistic sensitivity analysis, it was verified that the cost of the treatment with noradrenaline could vary between Int$2,326.53 and Int$3,644.16, while costs related to the treatment using terlipressin are not variable.  Conclusion  - The treatment strategy using terlipressin was more economical than that using noradrenaline under the perspective of the Brazilian Public Health System as the third-party payer.<\/jats:p>","DOI":"10.1590\/s0004-28032016000200014","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T13:35:43Z","timestamp":1465392943000},"page":"123-126","source":"Crossref","is-referenced-by-count":13,"title":["TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System"],"prefix":"10.1590","volume":"53","author":[{"given":"\u00c2ngelo Zambam de","family":"MATTOS","sequence":"first","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre,  Brazil; Irmandade Santa Casa de Miseric\u00f3rdia de Porto Alegre,  Brasil; Hospital Nossa Senhora da Concei\u00e7\u00e3o,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Alves de","family":"MATTOS","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre,  Brazil; Irmandade Santa Casa de Miseric\u00f3rdia de Porto Alegre,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Antonini","family":"RIBEIRO","sequence":"additional","affiliation":[{"name":"Instituto para Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade,  Brasil; Universidade Federal do Rio Grande do Sul,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria C","year":"2007","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2013.04.036","article-title":"A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis","volume":"59","author":"Fagundes C","year":"2013","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome a randomized pilot study","volume":"33","author":"Ghosh S","year":"2013","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud LL","year":"2010","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed M","year":"2008","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MEG.0000000000000537","article-title":"Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome systematic review with meta-analysis and full economic evaluation","volume":"28","author":"Mattos AZ","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau R","year":"2013","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107466","article-title":"Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome a systematic review and meta-analysis","volume":"9","author":"Nassar Junior AP","year":"2014","journal-title":"PLoS One"},{"key":"ref9","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno F","year":"2007","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma P","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: a randomized study.J","volume":"56","author":"Singh V","year":"2012","journal-title":"Hepatol"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v53n2\/0004-2803-ag-53-02-00123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T13:31:11Z","timestamp":1495546271000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032016000200123&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0004-28032016000200123"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032016000200014","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}